Neurogene (NGNE) Operating Margin (2018 - 2024)

Neurogene (NGNE) posted Operating Margin of 2176.65% for Q2 2024, down 36472.5% on a QoQ basis from 5.95% in Q3 2019.

Neurogene (NGNE) Operating Margin (2018 - 2024) Analysis & Trends

Neurogene's Operating Margin history runs 3 years deep, the most recent figure standing at 2176.65% for Q2 2024.

Quarterly Operating Margin changed N/A year-over-year to 2176.65% in Q2 2024, while the trailing twelve-month figure through Jun 2025 was 10345.08% (down 290022.0% YoY) and the FY2024 annual result came in at 8930.27%, changed N/A from the prior year.
Operating Margin was 2176.65% for Q2 2024 at Neurogene, down from 5.95% in the prior quarter.
Across five years, Operating Margin topped out at 2176.65% in Q2 2024 and bottomed at 2176.65% in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	16.51%
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	17.83%
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	30.35%
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Neurogene	776.69 Mn	776.69 Mn	-	-

Download Data